Characteristics of Patients Initiating Inclisiran in the Real World: A Retrospective Analysis of a US Database

Inclisiran was approved by the U.S. Food and Drug Administration (FDA) in December 2021 as an adjunct to diet and maximally tolerated statin for adults with clinical atherosclerotic cardiovascular disease (ASCVD) or heterozygous familial hypercholesterolemia (HeFH). It is a first in class small interfering RNA administered subcutaneously twice yearly. Studies assessing the real-world use of inclisiran in the United States (US) are scant.

Source: Journal of Clinical Lipidology - July 1, 2023 Category: Lipidology Authors: Xiaoli Niu, Akhil Parlapalli, Xinshuo Ma, Jina Park, Sean McElligott, Abena Osei-Wusu Tags: Novel Therapies in Lipid Management and Co-Morbidities Source Type: research